Cablivi

Drug Overview

Cablivi is a groundbreaking medication in the field of hematology. Designed to treat a rare, acute, and life-threatening blood clotting disorder, it represents a major advancement in how hematologists manage sudden vascular crises. Classified as an Anti-vWF Nanobody, this medication acts as a highly specialized Biologic and Targeted Therapy to stop the formation of dangerous micro-clots in the bloodstream.

For patients experiencing the terrifying sudden onset of Acquired Thrombotic Thrombocytopenic Purpura (aTTP), the primary goal is to halt the destruction of blood cells and prevent organ damage. Cablivi provides an essential bridge, working alongside traditional therapies to rapidly stabilize the patient’s blood flow and improve survival rates during the most critical phases of the disease.

• Generic Name: caplacizumab-yhdp
• US Brand Names: Cablivi
• Drug Category: Hematology
• Drug Class: Anti-vWF Nanobody (von Willebrand Factor-Directed Antibody Fragment)
• Route of Administration: Intravenous (IV) injection followed by daily Subcutaneous (SC) injections.
• FDA Approval Status: FDA-approved for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

What Is It and How Does It Work? (Mechanism of Action)

To understand how Cablivi works, we must first look at the condition it treats. In a healthy body, a protein called von Willebrand factor (vWF) floats in the blood like a coiled-up string. When you get a cut, this string uncoils, acting like a net to catch platelets and form a clot to stop the bleeding. A specific enzyme called ADAMTS13 acts like a pair of scissors, cutting these vWF strings so they do not get too long and cause unnecessary clots.

In patients with acquired Thrombotic Thrombocytopenic Purpura (aTTP), the body’s immune system mistakenly attacks and disables the “scissors” (ADAMTS13). Without ADAMTS13, the ultra-long vWF strings remain in the blood, catching platelets and forming hundreds of tiny clots inside the smallest blood vessels. This blocks blood flow to critical organs (like the brain, heart, and kidneys) and consumes the body’s supply of platelets, leading to a high risk of dangerous internal bleeding elsewhere.

Cablivi works as a highly precise Targeted Therapy. It is a “nanobody”—a miniature antibody designed to seek out and bind strictly to the A1 domain of the von Willebrand factor. By attaching itself directly to this specific part of the vWF protein, Cablivi physically blocks platelets from sticking to the vWF strings. While it does not fix the underlying lack of the “scissors” enzyme (which is why patients still need plasma exchange and immunosuppressants), it instantly stops the dangerous micro-clots from forming. This protects the organs and allows the patient’s circulating platelet count to recover safely.

FDA-Approved Clinical Indications

Primary Indication

Cablivi is specifically indicated for the treatment of adult patients experiencing an episode of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). It is used strictly in combination with daily therapeutic plasma exchange (PLEX) and immunosuppressive therapy (such as corticosteroids). By utilizing this Biologic alongside plasma exchange, hematologists can achieve a much faster recovery of the patient’s platelet levels and significantly reduce the risk of the disease flaring up again during the critical recovery period.

Other Approved & Off-Label Uses

Because Cablivi is highly specialized to target the von Willebrand factor, its uses are carefully restricted.

• Approved: Adult aTTP episodes.
• Off-Label Uses: While not formally approved, it is occasionally investigated in clinical settings for other severe immune-mediated thrombotic microangiopathies (disorders where tiny clots form in small blood vessels) that show a strong von Willebrand factor dependence, though such use is strictly experimental and under heavy hematological supervision.

Dosage and Administration Protocols

The administration of Cablivi is closely tied to the patient’s plasma exchange schedule and takes place in both inpatient and outpatient settings.

Important Adjustments:

• Treatment Extension: If the patient’s ADAMTS13 enzyme levels remain critically low after the initial 30 days, treatment may be extended for up to an additional 28 days to prevent an immediate relapse.
• Hepatic Insufficiency: No dose adjustment is needed for mild liver impairment, but Cablivi should be used with extreme caution in patients with severe hepatic impairment due to the increased baseline risk of bleeding.
• Missed Dose: If a dose is missed during the post-plasma exchange period, it can be administered if within 12 hours of the scheduled time. If more than 12 hours have passed, the missed dose should be skipped.

Clinical Efficacy and Research Results

The approval and ongoing use of Cablivi (2020-2026 data) are backed by robust clinical evidence, most notably the pivotal Phase 3 HERCULES trial.

In clinical trials involving acute aTTP patients, adding this Targeted Therapy to standard plasma exchange and immunosuppression resulted in a significantly faster recovery of platelet counts. Specifically, patients receiving Cablivi were 1.5 times more likely to achieve a normal platelet count at any given time point compared to those on a placebo.

Furthermore, clinical data demonstrates that Cablivi reduced the rate of disease exacerbations (flares) and completely halted aTTP-related deaths during the study period. It also significantly reduced the number of days patients required plasma exchange and the duration of their intensive care unit (ICU) stays, drastically improving overall survival and recovery trajectories for this severe blood disorder.

Safety Profile and Side Effects

Black Box Warning

There is no FDA “Black Box Warning” for Cablivi.

Common side effects (>10%)

Because this medication intentionally prevents platelets from clotting, the most common adverse reactions are related to mild or moderate bleeding:

• Epistaxis (nosebleeds)
• Gingival bleeding (bleeding gums)
• Headache
• Fatigue
• Fever
• Urticaria (hives)

Serious adverse events

• Severe Hemorrhage: Major, potentially life-threatening bleeding events, including gastrointestinal bleeding or intracranial hemorrhage (bleeding in the brain), particularly if the patient has a history of bleeding disorders or severe untreated high blood pressure.
• Hypersensitivity: Severe allergic reactions to the drug formulation.

Management Strategies

If a patient experiences severe or clinically significant bleeding while on Cablivi, the medication must be withheld immediately. Because the drug strongly binds to the von Willebrand factor, administering von Willebrand factor concentrate (along with other supportive bleeding management measures) may be required by the medical team to rapidly reverse the anti-clotting effects.

Research Areas

Ongoing hematological research is exploring the broader applications of nanobody technology. Clinical trials are investigating the long-term outcomes of aTTP patients treated with caplacizumab to see if rapid micro-clot resolution prevents chronic, long-term kidney or neurological damage. Additionally, researchers are studying advanced Immunotherapy and targeted delivery systems to see if Anti-vWF properties can be applied to other acute cardiovascular blockages without triggering systemic bleeding risks.

Disclaimer: These studies regarding caplacizumab for the prevention of long-term neurological damage and its application in acute cardiovascular blockages are based on ongoing clinical trials and longitudinal follow-ups. While they represent a major shift toward “organ-sparing” medicine, they require finalized global data to confirm their efficacy across all cardiovascular scenarios.

Patient Management and Practical Recommendations

Pre-treatment Tests

Before starting Cablivi, a hematology team will establish a clinical baseline:

• Complete Blood Count (CBC): To monitor platelet counts and hemoglobin levels daily.
• ADAMTS13 Activity: A crucial blood test to confirm the diagnosis of aTTP and monitor disease recovery.
• Coagulation Studies: PT, aPTT, and vWF antigen levels to assess baseline bleeding risk.
• Organ Function: Liver and kidney panels to assess any micro-clot damage that has already occurred.

Precautions during treatment

• Bleeding Vigilance: Medical teams must monitor the patient constantly for signs of internal bleeding, such as sudden confusion, severe headaches, dark tarry stools, or blood in the urine.
• Transfusion Triggers: Platelet transfusions are generally avoided in active aTTP because they can “feed” the micro-clots. However, if life-threatening hemorrhage occurs, standard transfusion and reversal protocols are strictly utilized.
• Discontinuation for Surgery: Cablivi should be interrupted at least 7 days prior to elective surgery or dental procedures to prevent uncontrolled bleeding.

“Do’s and Don’ts” List

• DO report any unusual bleeding, including heavy menstrual bleeding, persistent nosebleeds, or sudden unexplained bruising, to your doctor immediately.
• DO carry a medical alert card stating that you are taking an Anti-vWF medication.
• DO use a soft-bristled toothbrush and an electric razor to minimize the risk of cuts and gum bleeding.
• DON’T take over-the-counter NSAIDs (like ibuprofen, aspirin, or naproxen) without your hematologist’s explicit permission, as these further increase bleeding risks.
• DON’T engage in high-impact or contact sports while receiving this treatment and for at least a month afterward.

Legal Disclaimer

For informational purposes only, does not replace professional medical advice from a qualified healthcare provider. The information in this guide is intended to help patients and providers understand the general use of Cablivi. Because Acquired Thrombotic Thrombocytopenic Purpura (aTTP) is a complex medical emergency, all treatment decisions, dosage adjustments, and safety protocols must be strictly guided by a licensed specialist hematologist or attending physician.